Cargando…
Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor
Autor principal: | Coleman, RE |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284880/ http://dx.doi.org/10.1186/bcr2277 |
Ejemplares similares
-
Cytomics of the tumour microenvironment: therapeutic targeting (keynote lecture)
por: Smith, Paul
Publicado: (2015) -
From discovery of RANKL to clinical application of anti-human RANKL antibody
por: Yasuda, Hisataka, et al.
Publicado: (2012) -
Regulation of RANKL signaling in arthritic bone destruction
por: Takayanagi, H
Publicado: (2003) -
OA11 Osteoporosis, denosumab, and hypocalcaemia in multimorbid renal impairment
por: Daurat, Jean-Luc, et al.
Publicado: (2023) -
RANKL expression in human T-lymphocytes requires cooperative signaling through the T-cell receptor and adhesion molecule CD2
por: Harvey, B P, et al.
Publicado: (2010)